Ken Shao

Research Analyst at Morgan Stanley

Ken Shao is an Executive Director and Equity Analyst at Morgan Stanley, specializing in China healthcare and pharmaceuticals research. He covers a broad roster of companies, including CSPC Pharmaceutical Group, Hansoh Pharmaceutical, Innovent Biologics, and WuXi AppTec, and has been recognized for delivering actionable, high-conviction investment recommendations with a solid track record documented by top analyst rankings and strong average returns on platforms like TipRanks, where he maintains a high success rate. Shao began his career with roles at CICC and Deutsche Bank before joining Morgan Stanley in 2015, building a reputation for rigorous sector coverage and in-depth industry knowledge. He holds several professional credentials, including FINRA registration and securities licenses such as Series 7 and 63.